Receptor-type protein tyrosine phosphatases in cancer / 癌症

Protein tyrosine phosphatases (PTPs) play an important role in regulating cell signaling events in coordination with tyrosine kinases to control cell proliferation, apoptosis, survival, migration, and invasion. Receptor-type protein tyrosine phosphatases (PTPRs) are a subgroup of PTPs that share a transmembrane domain with resulting similarities in function and target specificity. In this review, we summarize genetic and epigenetic alterations including mutation, deletion, amplification, and promoter methylation of PTPRs in cancer and consider the consequences of PTPR alterations in different types of cancers. We also summarize recent developments using PTPRs as prognostic or predictive biomarkers and/or direct targets. Increased understanding of the role of PTPRs in cancer may provide opportunities to improve therapeutic approaches.

[Ceramide can induce leukocyte common antigen-related [lar] gene at mrna and protein level in c2c12 muscle cells]

Type 2 diabetes results from two defects, insulin resistance and beta cell dysfunction. At the molecular and cellular levels, there is a connection between fatty acid accumulation and insulin resistance in muscles. Although several mechanisms involved in FFA-induced muscle insulin resistance, the exact mechanism is poorly understood. Recent studies show that the defect in insulin signaling pathway might be underlying mechanism for FFA-induced insulin resistance in the muscle. Protein tyrosine phosphatases like Leukocyte common antigen-related [LAR] are the key elements of insulin signaling and they can be a candidate in FFA induced insulin resistance. Studies have shown that type 2 diabetes involved and obese individuals have had increased levels of LAR in their tissues. However, the responsible factor for LAR overexpression is not well understood. In this study we investigate ceramide effect on LAR expression in the muscle cells. In this laboratory study C2C12 cells [mouse skeletal] after differentiation to myotubes using 2% of horse serum for 4 days, treated with 50 and 100 mMs of C2ceramide for 16h. RNA extracted, cDNA synthesized and Real Time PCR using specific primers for LAR and beta actin used. To detect LAR protein levels western blot was used. 100 mMs Ceramide [45%, P<0.01] significantly induced LAR mRNA expression but there was not significant difference between 50mM ceramide and untreated cells. The results from real time confirmed by protein data. 100 mMs Ceramide [52%, P<0.01] significantly induced LAR protein levels in comparison of control. The data from this study provide evidence that ceramide around pathologic concentration induce LAR expression. Results supported by human studies that were showed that diabetic and obese persons have a high level of LAR expression and revealed ceramide can be one of the responsible factors for inducing LAR expression in diabetic patients. However, further investigations are needed to clarify exact role of LAR in FFA induced insulin resistance.